AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 201
Study 16627032 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive
Number of subjects: 201
Study 14564679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 12 weeks
Number of subjects: 0
Study 14564679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10964188 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapies (specific therapies not detailed)
Number of subjects: 0
Study 10964188 — intervention group
Group type: COMPARATOR
Intervention: Randomized control trials (RCTs)
Number of subjects: 0
Study 10964188 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapy research methods
Number of subjects: 0
Study 9006241 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group program
Number of subjects: 191
Study 1620831 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 160‐mL dose of Optiray 320 (ioversol) at 3.0 mL/sec (group 1)
Number of subjects: 50
Study 1620831 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 160‐mL dose of Optiray 320 (ioversol) at 4.5 mL/sec (group 2)
Number of subjects: 50
Study 1620831 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 50
Study 6736339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 8‐methoxypsoralen photochemotherapy (PUVA)
Number of subjects: 10
Study 31237065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (PEA-um) 15 mg/kg per os, once daily; n=29
Number of subjects: 57
Study 31237065 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n=28
Number of subjects: 57
Study 29439942 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot delivering telehealth care for 4 months
Number of subjects: 60
Study 29439942 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 60
Study 26718899 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 46
Study 26718899 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 46
Study 26718899 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy in venous ulcers
Number of subjects: 46
Study 26718899 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings in venous ulcers
Number of subjects: 46
Study 25163699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lexaptepid
Number of subjects: 24
Study 25163699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22161738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 10-16 mg/day
Number of subjects: 2401
Study 22161738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone 20-24 mg/day
Number of subjects: 2401
Study 22161738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2401
Study 22161738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (all doses)
Number of subjects: 2401
Study 22161738 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (higher doses)
Number of subjects: 2401
Study 19880504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg every 8 h for 3 days)
Number of subjects: 9
Study 19880504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17598699 — intervention group
Group type: EXPERIMENTAL
Intervention: Test FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Number of subjects: 24
Study 17598699 — intervention group
Group type: COMPARATOR
Intervention: Reference FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Number of subjects: 24
Study 15128070 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 110
Study 15128070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11496091 — intervention group
Group type: EXPERIMENTAL
Intervention: New ECG trigger method (group 1)
Number of subjects: 214
Study 11496091 — intervention group
Group type: COMPARATOR
Intervention: 80% R‐R interval trigger method (group 2)
Number of subjects: 214
Study 9728854 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of clonidine (4 microg/kg in 20 min followed by 2 microg x kg(‐1) x h(‐1))
Number of subjects: 60
Study 9728854 — intervention group
Group type: COMPARATOR
Intervention: IV infusion of sufentanil (0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 60
Study 9728854 — intervention group
Group type: COMPARATOR
Intervention: IV infusion of ketamine (0.5 mg/kg followed by 0.25 mg x kg(‐1) x h(‐1))
Number of subjects: 60
Study 9728854 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of bupivacaine (7 mL of 0.5% followed by 5 mL/h of 0.25%)
Number of subjects: 60
Study 8034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic device
Number of subjects: 91
Study 8034875 — intervention group
Group type: COMPARATOR
Intervention: Monophasic device
Number of subjects: 91
Study 2658536 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (30 g in 200 mL water)
Number of subjects: 0
Study 2658536 — intervention group
Group type: COMPARATOR
Intervention: Glucose (30 g in 200 mL water)
Number of subjects: 0
Study 2658536 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (30 g)
Number of subjects: 0
Study 2658536 — intervention group
Group type: COMPARATOR
Intervention: Glucose (30 g)
Number of subjects: 0
Study 10944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloride preparation of oxytetracycline
Number of subjects: 0
Study 10944 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated tablets of oxytetracycline dihydrate
Number of subjects: 0
Study 10944 — intervention group
Group type: COMPARATOR
Intervention: Sugar-coated tablets of oxytetracycline dihydrate
Number of subjects: 0
Study 31610828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3
Study 30329224 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-395 0.5/1000 mg
Number of subjects: 42
Study 30329224 — intervention group
Group type: COMPARATOR
Intervention: Coadministration of lobeglitazone sulfate 0.5 mg and metformin HCl XR 1000 mg
Number of subjects: 42
Study 29097660 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 62
Study 29097660 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 62
Study 29097660 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (Low and High cortisol responders)
Number of subjects: 62
Study 29097660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 26011583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency EMA (six times daily)
Number of subjects: 110
Study 26011583 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency EMA (once daily)
Number of subjects: 110
Study 24002488 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine promotion intervention
Number of subjects: 12
Study 24002488 — intervention group
Group type: COMPARATOR
Intervention: Mass azithromycin distribution
Number of subjects: 12
Study 21959871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for all HER2-positive populations
Number of subjects: 0
Study 21959871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for IHC 2+/FISH+ or IHC 3+ population
Number of subjects: 0
Study 21959871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for IHC 3+ population
Number of subjects: 0
Study 19843557 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521) plus AIDSVAX B/E vaccine regimen
Number of subjects: 16402
Study 16313821 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (digestive tract reconstruction by manual end-to-side anastomosis of residual stomach and jejunum, end-to-side anastomosis of residual duodenum and jejunum, and side-to-side anastomosis of jejunum and jejunum)
Number of subjects: 54
Study 16313821 — intervention group
Group type: COMPARATOR
Intervention: Group B (Bilroth digestive tract reconstruction)
Number of subjects: 54
Study 16313821 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 54
Study 16313821 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 54
Study 12142757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative retrobulbar 95% ethanol injections
Number of subjects: 11
Study 12142757 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar 0.75% bupivacaine with 1:100,000 epinephrine
Number of subjects: 11
Study 9990383 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone‐17‐valerate
Number of subjects: 1
Study 7532878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study 1972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms twice daily
Number of subjects: 16
Study 1972599 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms twice daily
Number of subjects: 16
Study 336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded doses of lactose (0 to 18 g) in breakfast meals, randomized and double-blinded.
Number of subjects: 59
Study 336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose equivalent to 1 to 1 1/2 glasses of milk taken with a meal.
Number of subjects: 59
Study 31823902 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP with minoxidil
Number of subjects: 80
Study 31823902 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP alone
Number of subjects: 80
Study 31823902 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil alone
Number of subjects: 80
Study 31823902 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 80
Study 31151360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers
Number of subjects: 15
Study 28653776 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call
Number of subjects: 1188
Study 28653776 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 1188
Study 28653776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1188
Study 25568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 6-minute walk distance (6MWD)
Number of subjects: 326
Study 25568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry steps
Number of subjects: 326
Study 25568929 — intervention group
Group type: COMPARATOR
Intervention: GOLD classification
Number of subjects: 326
Study 23668668 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 0
Study 23668668 — intervention group
Group type: COMPARATOR
Intervention: Therapists and trained raters
Number of subjects: 0
Study 21326115 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal pouch
Number of subjects: 30
Study 21326115 — intervention group
Group type: COMPARATOR
Intervention: Adult containment brief
Number of subjects: 30
Study 19335751 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a dosage of 90 microg kg(‐1) repeated every 3 h if needed
Number of subjects: 2000
Study 19335751 — intervention group
Group type: COMPARATOR
Intervention: Activated prothrombin complex concentrate (aPCC) at a dosage of 75 IU kg(‐1) repeated every 12 h if needed
Number of subjects: 2000
Study 17045492 — intervention group
Group type: EXPERIMENTAL
Intervention: Eigenimage classification model
Number of subjects: 60
Study 15286957 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 99
Study 15286957 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 99
Study 11560814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus caffeine
Number of subjects: 0
Study 11560814 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 11560814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9630111 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with LEAD and CAD
Number of subjects: 1400
Study 9630111 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetics with LEAD and CAD
Number of subjects: 1400
Study 9630111 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting surgery
Number of subjects: 1400
Study 7524203 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 101
Study 7524203 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 101
Study 3350031 — intervention group
Group type: COMPARATOR
Intervention: Intervention not specified in the abstract, but involved antihypertensive regimens.
Number of subjects: 551
Study 29746373 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg
Number of subjects: 297
Study 29746373 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.625 mg
Number of subjects: 297
Study 29746373 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 297
Study 27039383 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing both A1 and A2 β‐casein
Number of subjects: 45
Study 27039383 — intervention group
Group type: COMPARATOR
Intervention: Milk containing only A2 β‐casein
Number of subjects: 45
Study 25708282 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL) with riboflavin (0.1 in 20 % dextran) and UVA radiation (365 nm, 3 mW/cm(2), 30 min)
Number of subjects: 43
Study 25708282 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 43
Study 25708282 — intervention group
Group type: COMPARATOR
Intervention: Sham group (riboflavin only, no UVA)
Number of subjects: 43
Study 23955482 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg Se/day as high‐Se yeast
Number of subjects: 16
Study 23955482 — intervention group
Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 16
Study 19856321 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 0
Study 19856321 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rate ratio model
Number of subjects: 0
Study 19856321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate difference model
Number of subjects: 0
Study 17890759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive lifestyle program focusing on weight loss, diet, and exercise; details on dosage and duration not specified.
Number of subjects: 241
Study 17890759 — intervention group
Group type: COMPARATOR
Intervention: Usual care; details on dosage and duration not specified.
Number of subjects: 241
Study 17890759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive lifestyle program; details on dosage and duration not specified.
Number of subjects: 241
Study 15983303 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental computer multimedia use (intervention)
Number of subjects: 244
Study 15983303 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (control)
Number of subjects: 244
Study 12473989 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term protocol (LTP) - 60 micro g PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no treatment for 40 weeks.
Number of subjects: 1276
Study 12473989 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term protocol (STP) - 60 micro g PGE1 twice a day for 2 days, repeated every 4 weeks.
Number of subjects: 1276
Study 12473989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of LTP protocol
Number of subjects: 1276
Study 12473989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of STP protocol
Number of subjects: 1276
Study 10520386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg (group T)
Number of subjects: 121
Study 10520386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 121
Study 10520386 — intervention group
Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 121
Study 8643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) and Doxorubicin (60 mg/m2) administered in alternating schedules (3-hour infusion for paclitaxel and intravenous bolus for doxorubicin)
Number of subjects: 54
Study 8643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and Doxorubicin (60 mg/m2) administered with a 30-minute doxorubicin infusion preceding a 3-hour paclitaxel infusion every 3 weeks
Number of subjects: 54
Study 8643964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose levels of paclitaxel/doxorubicin (175 mg/m2 and 60 mg/m2)
Number of subjects: 54
Study 8643964 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study 2343728 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 87
Study 2343728 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital 2 mg/kg
Number of subjects: 87
Study 2343728 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg
Number of subjects: 87
Study 2343728 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium
Number of subjects: 87
Study 7390377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromopride (one capsule three times daily for three weeks)
Number of subjects: 31
Study 7390377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule three times daily for three weeks)
Number of subjects: 31
Study 31910054 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) group
Number of subjects: 171
Study 31910054 — intervention group
Group type: COMPARATOR
Intervention: Open group
Number of subjects: 171
Study 31195195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-sensitive agricultural program
Number of subjects: 0
Study 28266082 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of EGCG daily until full term
Number of subjects: 404
Study 28266082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 26398484 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial working memory training (adaptive n-back spatial task)
Number of subjects: 48
Study 26398484 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive version of n-back task (control group)
Number of subjects: 48
Study 23641215 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1440115 (750 mg)
Number of subjects: 12
Study 23641215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21434335 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI) combined with conventional therapy
Number of subjects: 70
Study 21434335 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 70
Study 19162515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intermittent pneumatic leg compression and pharmacological prophylaxis
Number of subjects: 0
Study 19162515 — intervention group
Group type: COMPARATOR
Intervention: Single modalities (either intermittent pneumatic leg compression or pharmacological prophylaxis alone)
Number of subjects: 0
Study 16831525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 40
Study 16831525 — intervention group
Group type: COMPARATOR
Intervention: 17beta-estradiol
Number of subjects: 40
Study 16831525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 15088036 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐cured compomer with light‐cured dental adhesive
Number of subjects: 34
Study 15088036 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured glass ionomer
Number of subjects: 34
Study 11334133 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) such as beclomethasone, budesonide, and fluticasone
Number of subjects: 0
Study 11334133 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 10969345 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (HIV-1 RNA levels)
Number of subjects: 3859
Study 10969345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhites (HIV-1 RNA levels)
Number of subjects: 3859
Study 10969345 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with a history of injection drug use (HIV-1 RNA levels)
Number of subjects: 3859
Study 10969345 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (CD4+ cell count decline)
Number of subjects: 3859
Study 10969345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhites (CD4+ cell count decline)
Number of subjects: 3859
Study 9351739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast
Number of subjects: 192
Study 1479324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical screening invitation in advance with breast screening invitation (group 1)
Number of subjects: 2131
Study 1479324 — intervention group
Group type: COMPARATOR
Intervention: Breast screening only with cervical smear test offered upon arrival (group 2)
Number of subjects: 2131
Study 1479324 — intervention group
Group type: COMPARATOR
Intervention: Overall attendance for breast screening
Number of subjects: 2131
Study 1479324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical screening among those attending breast screening
Number of subjects: 2131
Study 1479324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical smear test overdue
Number of subjects: 2131
Study 3922903 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS 10 (10 mg nitroglycerin over 24 hours)
Number of subjects: 9
Study 3922903 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN (20 mg slow-release)
Number of subjects: 9
Study 3922903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30468108 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use prior to imprisonment; Alcohol (73%), Cigarettes (71%), Illicit drug use (27%), Injectable drug use (11%)
Number of subjects: 434
Study 30468108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse with sex workers; 204 inmates reported having intercourse with sex workers
Number of subjects: 434
Study 27126398 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychotherapies (TFPs)
Number of subjects: 0
Study 27126398 — intervention group
Group type: COMPARATOR
Intervention: Sertraline, venlafaxine, nefazodone
Number of subjects: 0